The Cutting-Edge Technology of AI Prostate Cancer Diagnosis in the Era of Digital Pathology
Digitization brought dramatic changes to the different parts of the healthcare industry. Pathology, a field in which the adoption of digitization has been quite slow compared to other fields, is now poised for the long-awaited transition to digitization. Gaining momentum as a proven and essential technology, digital pathology can be a great solution to resolve problems pathologists are facing increasing workload but not enough human resources to deal with it.
This presentation introduces an AI-powered cancer diagnostic support software for prostate cancer, the most common cancer among males. Integrated to the current workflow, the diagnostic support software can provide pathologists with meaningful benefits including minimizing the risk of human errors from the subjectivity of pathologist assessments, leading to more precise and consistent diagnostic results, and improved reproducibility.
At the same time, the talk elaborates on the cutting-edge deep learning system applied to the diagnostic software space, which overcame its limits for better performance and higher utilization.
At the end of the speech, the values of the cutting-edge technology that encompasses the entire journey of cancer care will be presented: diagnosis, prognosis, treatment.
The speech will enable the audience to gain a better understanding of the AI capabilities that can be integrated into the existing pathology workflow and change the current cancer treatment environment.
발표자 소개
Sun Woo Kim, the founder and CEO of a South Korean biotech start-up, Deep Bio Inc., has a proven track record of over 20 years in executive management as well as computer science expertise. He founded the company based on the strong belief that AI can bring about positive impacts and add value to different areas of the healthcare industry. Prior to founding Deep Bio, he served as the CTO of Pinion Industries, an automotive software and security start-up, which was acquired by Hyundai Motors in 2014. He was also the deputy director of Korea Telecommunications, the largest telephone operator in Korea, where he led the global venture capital team.
Leica Biosystems 콘텐츠는 Leica Biosystems 웹사이트 이용 약관의 적용을 받으며, 이용 약관은 다음에서 확인할 수 있습니다. 법적고지. 라이카 바이오시스템즈 웨비나, 교육 프레젠테이션 및 관련 자료는 특별 주제 관련 일반 정보를 제공하지만 의료, 규정 또는 법률 상담으로 제공되지 않으며 해석되어서는 안 됩니다. 관점과 의견은 발표자/저자의 개인 관점과 의견이며 라이카 바이오시스템즈, 그 직원 또는 대행사의 관점이나 의견을 나타내거나 반영하지 않습니다. 제3자 자원 또는 콘텐츠에 대한 액세스를 제공하는 콘텐츠에 포함된 모든 링크는 오직 편의를 위해 제공됩니다.
모든 제품 사용에 다양한 제품 및 장치의 제품 정보 가이드, 부속 문서 및 작동 설명서를 참조해야 합니다.
Copyright © 2024 Leica Biosystems division of Leica Microsystems, Inc. and its Leica Biosystems affiliates. All rights reserved. LEICA and the Leica Logo are registered trademarks of Leica Microsystems IR GmbH.